STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: There are several different TKIs that are Food and Drug Administration (FDA) approved for the treatment of CML, which is often dependent on STAT5 signalling, such as imatinib that inhibits Bcr-Abl, dasatinib and nilotinib [118,119].